Dipeptidyl peptidase-4 inhibitor anagliptin reduces fasting apolipoprotein B-48 levels in patients with type 2 diabetes: A randomized controlled trial

Type 2 diabetes and dyslipidemia are diseases that collectively increase the risk of patients developing cardiovascular complications. Several incretin-based drugs are reported to improve lipid metabolism, and one of these medications, anagliptin, is a dipeptidyl peptidase-4 (DPP-4) inhibitor that h...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:PLoS One
Main Authors: Onoue, Takeshi, Goto, Motomitsu, Wada, Eri, Furukawa, Mariko, Okuji, Takayuki, Okada, Norio, Kobayashi, Tomoko, Iwama, Shintaro, Sugiyama, Mariko, Tsunekawa, Taku, Takagi, Hiroshi, Hagiwara, Daisuke, Ito, Yoshihiro, Morishita, Yoshiaki, Seino, Yusuke, Suga, Hidetaka, Banno, Ryoichi, Hamada, Yoji, Ando, Masahiko, Yamamori, Etsuko, Arima, Hiroshi
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science 2020
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6986701/
https://ncbi.nlm.nih.gov/pubmed/31990936
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0228004
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados